Empaveli Positive Phase 3 VALIANT Results Published in NEJM
Topline: In the Phase 3 VALIANT trial for C3 glomerulopathy and primary IC-MPGN, pegcetacoplan cut proteinuria by 68% versus...
eClinical Tech News
CARES-310 Study Final Analysis Published in The Lancet
Camrelizumab plus rivoceranib delivered a median overall survival of 23.8 months versus 15.2 months on sorafenib in first-line unresectable...
First Patient Dosed in Crinetics’ Neuroendocrine Tumor Trial
Crinetics has dosed the first patient in BRAVESST2, a first-in-human Phase 1/2 study of CRN09682 in metastatic or locally...
Relmada Presents NDV-01 Phase 2 Urologic Oncology Data
NDV-01, a sustained-release intravesical gemcitabine/docetaxel formulation, has reported a 92% complete response at any time point at nine months...
Capricor’s Hopeful DMD Drug Sees Phase 3 Pivotal Victory
In the pivotal Phase 3 HOPE-3 trial (n=106), Deramiocel slowed decline on PUL v2.0 by 54% versus placebo (p=0.029)...
Italy Approves Betaglue’s Pancreatic Cancer Clinical Trial
BetaGlue Therapeutics has secured Italian Ministry of Health approval for a clinical investigation of YntraDose in unresectable locally advanced...
Phase 3 STELLAR Study Shows Improvements in Rare Brain Tumor
Median overall survival reached 34.9 months with eflornithine plus lomustine versus 23.5 months with lomustine alone in patients with...
New Nebokitug Phase 2 Results Published for Sclerosing Cholangitis
Nebokitug was safe and well tolerated through 48 weeks in primary sclerosing cholangitis, with a statistically significant reduction in...
A Breakthrough In Alcoholism Treatment: Clearmind Soars
Clearmind’s Phase I/IIa program for CMND-100 in alcohol use disorder has cleared an early safety gate: after dosing the...
Salarius, Texas Biomedical to Collaborate on Avian Flu Study
No clinical or in vitro efficacy data were reported. Decoy Therapeutics’ peptide conjugate influenza fusion inhibitors have only shown...